Main takeaway: A decision on Medicare coverage for its Cxbladder project is due next July, and an adverse decision could take years to fight.
The boss of dual-listed cancer diagnostics company Pacific Edge has reiterated that its belt has been “appropriately tightened” for the ongoing Medicare coverage uncertainty it faces in the United States and that it has enough cash for a process that could take years to resolve.
The company
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
